ProMIS Neurosciences Inc.

The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for best in class treatment of neurodegenerative diseases, in particular, Alzheimer's disease (AD) and ALS. ProMIS Neurosciences' proprietary target discovery engine is based on two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the surface of misfolded proteins. ProMIS has identified five target sites on toxic, misfolded strains of amyloid beta, a known root cause of Alzheimer's, and created five antibodies specific to these targets (without targeting amyloid beta monomer or plaque, known to be related to poor efficacy and side effects). Results of prior clinical trials indicate best in class AD therapy should target specifically toxic, misfolded strains of amyloid beta and not the other forms. ProMIS' AD program is uniquely designed and on track to achieve this goal. The Company's lead antibody product, PMN310 is in late preclinical development, with initiation of clinical trials expected in 2019.

Expert Comments:

The company cites the recent discontinuation of other firms' clinical programs as proof.
read more >
headshot of André Uddin

André Uddin, Mackie Research Capital

"ProMIS Neurosciences Inc. has identified multiple targets for neurodegenerative disorders: an alpha synuclein for Parkinson's, tau for Alzheimer's and SOD1 and TDP43 for amyotrophic lateral sclerosis; we expect the company to outlicense these targets and related candidates. A licensing deal could be forged in Q2/19 or Q3/19 for one of these drug candidates; multiple players are currently at the table."

The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein.
read more >

André Uddin, Mackie Research Capital

"ProMIS Neurosciences Inc. is to initiate a Phase 1 study with PMN310 in both healthy subjects and prodromal/mild Alzheimer's patients (total n=8) in H2/19; results of this trial are expected in late 2020. Results of Biogen's Phase 3 ENGAGE trial with aducanumab are also expected in 2020; positive ENGAGE results could potentially enable ProMIS to piggyback on that data, enabling it to potentially outlicense PMN310."

Clive Maund,

"ProMIS Neurosciences Inc. is a biotech stock that is working out well for us. . .the long-term outlook for the company and its stock is excellent."

headshot of André Uddin

André Uddin, Mackie Research Capital

"Through its platform, ProMIS Neurosciences Inc. has identified multiple targets for various central nervous system disorders: SOD1 for amyotrophic lateral sclerosis (ALS), TDP43 for ALS, alpha-synuclein for Parkinson's and tau for Alzheimer's. . .we expect the company to out-license those targets/candidates. . .we expect a licensing deal to be forged in Q2/19 or Q3/19; multiple players are currently at the table."

Cosme Ordonez, Noble Capital Markets

"We are initiating coverage on ProMIS Neurosciences Inc. with an Outperform rating and a $1 target price. . .we believe the company's stock is undervalued and does not reflect the significant potential of its lead drug PMN310. The signing of a high value partnership could act as a key catalyst for the stock."

The Canadian company continues seeking partners to leverage its discovery and development platform.
read more >
This Canadian developer of therapeutics for neurodegenerative diseases bases its opinion, in part, on its own preclinical findings.
read more >
headshot of André Uddin

André Uddin, Mackie Research Capital

"ProMIS Neurosciences Inc. is looking to initiate a Phase 1 study with PMN310 in both healthy subjects and prodromal/mild Alzheimer's patients (a total of eight subjects) in H2/19. . .the company is looking to outlicense PMN310 after the Phase 1 study. . .it is looking to outlicense its anti-H-synuclein assets for Parkinson's disease."

This firm explains how its 15 years in drug development led to and supports this conclusion.
read more >
With this achievement, the firm expands its potential partnering opportunities.
read more >
Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates.
read more >

More Expert Comments

Experts Following This Company

Clive Maund –
headshot of André Uddin
André Uddin – Mackie Research Capital
John Vandermosten, CFA – Zacks Small-Cap Research

The information provided above is from analysts, newsletters, the company and other contributors.

ProMIS Neurosciences Inc. is a sponsor of Streetwise Reports. The company's sponsorship fees pay for Streetwise Reports to create and update this "Investor Summary Page," to which links are placed on Streetwise Reports' websites and newsletters. Streetwise Reports does not accept stock for the payment of fees. See disclaimer for more details.

The company description, investing highlights and catalyst calendar on this page were prepared by the company. The Expert Comments and Experts Following This Company sections of this page are compiled by Streetwise Reports. There may be other information about the company that is not placed on this page. Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on this page.

The Expert Opinions above are excerpted from third-party sources not affiliated with or controlled by Streetwise Reports. The statements or opinions expressed in the Expert Opinions above are those of the authors indicated, and Streetwise Reports has not verified the accuracy of material excerpted here. Publications excerpted above may receive payment or sponsorship from the company mentioned.

Streetwise Reports does not provide investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security.Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.

Readers should conduct their own research for all information publicly available concerning the company.